Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Among authors: panizo c. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M. Wang M, et al. Among authors: panizo c. Leukemia. 2019 Nov;33(11):2762-2766. doi: 10.1038/s41375-019-0575-9. Epub 2019 Sep 26. Leukemia. 2019. PMID: 31558766 Clinical Trial. No abstract available.
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
García-Noblejas A, Martínez Chamorro C, Navarro Matilla B, Da Silva Rodriguez C, González-Lopez TJ, Oña Navarrete R, Ramírez Sánchez MJ, Martínez Barranco P, Sánchez Blanco JJ, Nicolás C, Pérez R, Sánchez González B, Ruedas López AM, Domingo-Domenech E, Panizo C, Macia S, Fernández-Fonseca E, Cannata-Ortiz J, Arranz R. García-Noblejas A, et al. Among authors: panizo c. Ann Hematol. 2014 Sep;93(9):1551-8. doi: 10.1007/s00277-014-2077-1. Epub 2014 Apr 30. Ann Hematol. 2014. PMID: 24782117
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). Salar A, et al. Among authors: panizo c. Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19. Lancet Haematol. 2014. PMID: 27029228
Obinutuzumab in follicular lymphoma.
Martinez-Calle N, Figueroa-Mora R, Villar-Fernandez S, Marcos-Jubilar M, Panizo C. Martinez-Calle N, et al. Among authors: panizo c. Drugs Today (Barc). 2016 Dec;52(12):643-651. doi: 10.1358/dot.2016.52.12.2550578. Drugs Today (Barc). 2016. PMID: 28276536 Review.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Carpio C, et al. Among authors: panizo c. Blood. 2020 Mar 26;135(13):996-1007. doi: 10.1182/blood.2019002395. Blood. 2020. PMID: 31977002 Free PMC article.
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Halwani AS, et al. Among authors: panizo c. Leuk Lymphoma. 2022 Apr;63(4):821-833. doi: 10.1080/10428194.2021.2010057. Epub 2021 Dec 6. Leuk Lymphoma. 2022. PMID: 34865586 Clinical Trial.
Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M. Inoges S, et al. Among authors: panizo c. Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122. Leuk Lymphoma. 2009. PMID: 19152172 Free article.
114 results